The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
Global specialty pipeline accelerates growth
Company leadership is framing the move as transformational.
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
The product will be marketed by Dr. Reddy's Laboratories Inc.
Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region
Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals
The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA
This is Senores' second API manufacturing facility adding significantly to the existing API manufacturing capabilities.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
